Bin-yi Xiao

State Key Laboratory Of Oncology In South China
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Proposal of a novel model for identifying complete response and nonoperative management in dMMR colon cancer following neoadjuvant immunotherapy: a retrospective cohort study.

Proposal of a novel model for identifying complete response and nonoperative management in dMMR colon cancer following neoadjuvant immunotherapy: a retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: May 30, 2025

Proposal of a novel model for identifying complete response and nonoperative management in DMMR colon cancer following neoadjuvant immunotherapy: a retrospective cohort study.

Proposal of a novel model for identifying complete response and nonoperative management in DMMR colon cancer following neoadjuvant immunotherapy: a retrospective cohort study.

Journal: International journal of surgery (London, England)

Published: May 30, 2025

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.

Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study.

Journal: The Lancet. Oncology

Published: December 07, 2023

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment.

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti-PD-1-Based Immunotherapy as Curative-Intent Treatment.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: August 01, 2023

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.

Neoadjuvant Immunotherapy Leads to Major Response and Low Recurrence in Localized Mismatch Repair-Deficient Colorectal Cancer.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: June 11, 2022

Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study.

Anti-PD-1-based immunotherapy as curative-intent treatment in dMMR/MSI-H rectal cancer: A multicentre cohort study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 17, 2022

Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.

Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.

Journal: Diseases of the colon and rectum

Published: April 29, 2022

Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel.

Universal germline testing among patients with colorectal cancer: clinical actionability and optimised panel.

Journal: Journal of medical genetics

Published: June 02, 2020

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.

PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer.

Journal: Oncoimmunology

Published: July 07, 2019

Showing 1-9 of 9

Last Updated: 09/26/2026